Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

Background The levels and clinical relevance of Th17 cells and other interleukin-17-producing cells have not been analyzed in chronic lymphocytic leukemia. The objective of this study was to quantify blood and tissue levels of Th17 and other interleukin-17-producing cells in patients with this disease and correlate blood levels with clinical outcome. Design and Methods Intracellular interleukin-17A was assessed in blood and splenic mononuclear cells from patients with chronic lymphocytic leukemia and healthy subjects using flow cytometry. Interleukin-17A-producing cells were analyzed in formalin-fixed, paraffin-embedded spleen and lymph node sections using immunohistochemistry and immunofluorescence. Results The absolute numbers of Th17 cells in peripheral blood mononuclear cells and the percentages of Th17 cells in spleen cell suspensions were higher in patients with chronic lymphocytic leukemia than in healthy subjects; in six out of eight paired chronic lymphocytic leukemia blood and spleen sample comparisons, Th17 cells were enriched in spleen suspensions. Circulating Th17 levels correlated with better prognostic markers and longer overall survival of the patients. Two “non-Th17” interleukin-17-expressing cells were identified in chronic lymphocytic leukemia spleens: proliferating cells of the granulocytic lineage and mature mast cells. Granulocytes and mast cells in normal spleens did not express interleukin-17. Conversely, both chronic lymphocytic leukemia and healthy lymph nodes contained similar numbers of interleukin-17+ mast cells as well as Th17 cells. Conclusions Th17 cells are elevated in chronic lymphocytic leukemia patients with better prognostic markers and correlate with longer survival. Furthermore, non-Th17 interleukin-17A-expressing cells exist in chronic lymphocytic leukemia spleens as maturing granulocytes and mature mast cells, suggesting that the microenvironmental milieu in leukemic spleens promotes the recruitment and/or expansion of Th17 and other IL-17-expressing cells. The pathophysiology of Th17 and non-Th17-interleukin-producing cells in chronic lymphocytic leukemia and their distributions and roles in this disease merit further study.

[1]  W. Zou,et al.  Erratum: TH 17 cells in tumour immunity and immunotherapy (Nature Reviews Immunology (2010) 10 (248-256)) , 2011 .

[2]  L. Joosten,et al.  The anti-CD20 antibody rituximab reduces the Th17 cell response. , 2011, Arthritis and rheumatism.

[3]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[4]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2011, Nature Reviews Immunology.

[5]  Wentian Li,et al.  Identification of Distinct Cytokine and Chemokine Clusters That Correlate with Outcome In B-Cell Chronic Lymphocytic Leukemia: Implications for Disease Pathogenesis , 2010 .

[6]  L. Marchionni,et al.  A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. , 2010, Blood.

[7]  T. Hagemann,et al.  Up for Mischief? IL-17/Th17 in the tumour microenvironment , 2010, Oncogene.

[8]  X. Chen,et al.  Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. , 2010, Lung cancer.

[9]  S. Pileri,et al.  Immunopathology and Infectious Diseases Mast Cells and Th 17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma , 2010 .

[10]  Y. Iwakura,et al.  Tumor‐infiltrating IL‐17‐producing γδ T cells support the progression of tumor by promoting angiogenesis , 2010, European journal of immunology.

[11]  J. Kutok,et al.  Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. , 2010, Blood.

[12]  Ashley M. Miller,et al.  Mast cells express IL-17A in rheumatoid arthritis synovium. , 2010, Journal of immunology.

[13]  P. Teeling,et al.  Differential expression of interleukin‐17 family cytokines in intact and complicated human atherosclerotic plaques , 2010, The Journal of pathology.

[14]  H. Döhner,et al.  Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells , 2010, British journal of haematology.

[15]  G. Shen,et al.  Mast Cells Mobilize Myeloid-Derived Suppressor Cells and Treg Cells in Tumor Microenvironment via IL-17 Pathway in Murine Hepatocarcinoma Model , 2010, PloS one.

[16]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[17]  H. Xu,et al.  Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia , 2009, Clinical and experimental immunology.

[18]  A. Rosenwald,et al.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies. , 2009, Blood.

[19]  B. Saha,et al.  Protumor vs Antitumor Functions of IL-171 , 2009, The Journal of Immunology.

[20]  M. Banerjee,et al.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. , 2009, Blood.

[21]  S. Gaffen.  Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.

[22]  S. Ansell,et al.  Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. , 2009, Cancer research.

[23]  L. Cosmi,et al.  Type 17 T helper cells—origins, features and possible roles in rheumatic disease , 2009, Nature Reviews Rheumatology.

[24]  J. Xu,et al.  Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. , 2009, Journal of Hepatology.

[25]  Mohamed El-behi,et al.  IL-23 Drives Pathogenic IL-17-Producing CD8+ T Cells1 , 2009, The Journal of Immunology.

[26]  W. Born,et al.  IL‐17‐producing γδ T cells , 2009, European journal of immunology.

[27]  W. Born,et al.  IL‐17‐producing γδ T cells , 2009, European Journal of Immunology.

[28]  P. Miossec.  Diseases that may benefit from manipulating the Th17 pathway , 2009, European journal of immunology.

[29]  S. Jagannath,et al.  Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. , 2008, Blood.

[30]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[31]  M. Caligiuri,et al.  IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. , 2008, Blood.

[32]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[33]  Chi‐Huey Wong,et al.  Identification of an IL-17–producing NK1.1neg iNKT cell population involved in airway neutrophilia , 2007, The Journal of experimental medicine.

[34]  Muthusamy,et al.  IL-21 Mediates Apoptosis Through Up-Regulation of the BH3 Family Member BIM and Enhances both Direct and Antibody Dependent Cellular Cytotoxicity in Primary Chronic Lymphocytic Cells , 2007 .

[35]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[36]  G. Jovčić,et al.  The effect of interleukin-17 on hematopoietic cells and cytokine release in mouse spleen. , 2007, Physiological research.

[37]  R. Wu,et al.  Up-Regulation of CC Chemokine Ligand 20 Expression in Human Airway Epithelium by IL-17 through a JAK-Independent but MEK/NF-κB-Dependent Signaling Pathway1 , 2005, The Journal of Immunology.

[38]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[39]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[40]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.